scholarly journals Unilateral minimal ovarian cancer with peritoneal implant and an intraepithelial carcinoma in the contralateral fallopian tube

2017 ◽  
Vol 6 (4) ◽  
pp. 1679
Author(s):  
Hiroyuki Terada ◽  
Ken-ichi Honda ◽  
Tomoko Nakagawa ◽  
Aki Takase ◽  
Yasushi Kurihara ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Fallopian Tube ◽  
Left Ovary ◽  
Serous Adenocarcinoma ◽  
Massive Ascites ◽  
Ovarian Serous Adenocarcinoma ◽  
Inner Surface ◽  
Peritoneal Implant ◽  
Intraepithelial Carcinoma

Here we present postoperative pathology of an 82-year-old woman who presented with massive ascites, and an implant-like adenocarcinoma on her intrapelvic peritoneum, which revealed a minimal (<5mm) serous adenocarcinoma on her left ovary and an intraepithelial carcinoma on inner surface of her right Fallopian tube.  The left ovarian serous adenocarcinoma may have originated as an intraepithelial carcinoma on contralateral Fallopian tube.

Ovarian carcinoma in a 14-year-old with classical salt-wasting congenital adrenal hyperplasia and bilateral adrenalectomy

2015 ◽  
Vol 28 (5-6) ◽  
Author(s):  
Christian Pina ◽  
Ahmed Khattab ◽  
Philip Katzman ◽  
Lauren Bruckner ◽  
Jeffrey Andolina ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Ovarian Carcinoma ◽  
Left Ovary ◽  
Bilateral Adrenalectomy ◽  
Ca 125 ◽  
Adrenal Hyperplasia ◽  
Serous Adenocarcinoma ◽  
Adrenal Tissue ◽  
Ovarian Serous Adenocarcinoma ◽  
21 Hydroxylase Deficiency

AbstractA 14-year-old female with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency underwent bilateral adrenalectomy at 6 years of age as a result of poor hormonal control. Because the patient was adrenalectomized, extra adrenal androgen production was suspected. Imaging studies including pelvic ultrasound and pelvic magnetic resonance imaging (MRI) were obtained to evaluate for adrenal rest tumors of the ovaries. Abdominal MRI was obtained to evaluate for residual adrenal tissue. A cystic lesion arising from her right ovary suspicious for ovarian neoplasm was noted on pelvic MRI. Right salpingo-oophorectomy was performed and histopathological examination revealed ovarian serous adenocarcinoma, low-grade, and well-differentiated. Tumor marker CA-125 was elevated and additional ovarian cancer staging workup confirmed stage IIIC due to one lymph node positive for carcinoma. The patient then developed a large left ovarian cyst, which led to a complete total abdominal hysterectomy and removal of the left ovary and fallopian tube. Pathology confirmed ovarian serous adenocarcinoma with microscopic focus of carcinoma in the left ovary. After numerous complications, the patient responded well to chemotherapy, CA-125 levels fell and no evidence of carcinoma was observed on subsequent imaging. To our knowledge, this is the first reported case of an ovarian serous adenocarcinoma in a patient with CAH. Although rare, we propose that the ovaries were the origin of androgen production and not residual adrenal tissue. The relationship between CAH and ovarian carcinomas has yet to be established, but further evaluation is needed given the poor survival rate of high-grade serous ovarian carcinoma.

scholarly journals Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Junzheng Yang ◽  
Yilan Zhou ◽  
Shu-Kay Ng ◽  
Kuan-Chun Huang ◽  
Xiaoyan Ni ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Fallopian Tube ◽  
Intraepithelial Carcinoma

scholarly journals Implication of BAG5 Downregulation in Metabolic Reprogramming of Cisplatin-resistant Ovarian Cancer Cells via mTORC2 Signaling Pathway

2020 ◽  
Author(s):  
Jia-Mei Wang ◽  
Qi Zhang ◽  
Liang Hao ◽  
Jing-Yi Jiang ◽  
Ling-Yue Huyan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Signaling Pathway ◽  
Cisplatin Resistance ◽  
Metabolic Reprogramming ◽  
Migration And Invasion ◽  
Ovarian Cancer Cells ◽  
Serous Adenocarcinoma ◽  
Metabolism Regulation ◽  
Ovarian Serous Adenocarcinoma

Abstract Background: Ovarian cancer is the most frequent cause of death among gynecologic malignancies due to the absence of an early effective diagnostic approach. Although the majority of patients typically respond well to the first line of chemotherapy based on platinum compounds and taxanes, recurrence and chemoresistance limits its clinical utility. Remarkably, cancer stem cells (CSC) tend to form minimal residual disease after chemotherapy and exhibit recurrent potential. The ability of cancer cells to reprogram their metabolism has recently been related with resistance to chemotherapies.Methods: BAG5 expression was studied in 16 cisplatin-sensitive and 8 cisplatin-resistant ovarian cancer tissues by Western blot. BAG5-induced cell proliferation, migration and invasion were investigated by CCK-8 assay, colony formation assay, wound healing and Transwell assay. To investigate whether BAG5 is implicated in metabolism regulation, mitochondrial function was monitored by real-time measurement of changes in the oxygen consumption rate (OCR) and glycolysis was also determined by measuring the extracellular acidification rate (ECAR). Immunohistochemical staining measured correlations between BAG5 and Bcl6, Rictor in most ovarian serous adenocarcinoma tissues.Results: The current study found BAG5 expression was decreased in cisplatin-resistant ovarian cancer cells and clinical tissues. Our data demonstrated that BAG5 knockdown was implicated in metabolic reprogramming and maintenance of cancer stem cell (CSC)-like features of cisplatin-resistant ovarian cancer cells via regulation of Rictor and subsequent mTORC2 signaling pathway. In addition, the current study demonstrated that Bcl6 upregulation was responsible for repression of BAG5 transactivation via recruitment on the BAG5 promoter in cisplatin-resistant ovarian cancer. The current study also demonstrated reverse correlations between BAG5 and Bcl6, BAG5 and Rictor in ovarian serous adenocarcinoma tissues. Conclusions: Collectively, the current study identified the implication of Bcl6/BAG5/Rictor-mTORC2 signaling pathway in metabolic reprograming and maintenance of CSC-like features including cisplatin-resistance in cisplatin-resistant ovarian cancer cells. Therefore, further studies on the mechanism underlying regulation of metabolic reprogramming and CSC-like characteristics of cisplatin-resistant ovarian cancer cells may contribute to the establishment of novel therapeutic strategy for cisplatin-resistance.

scholarly journals Updates on FIGO Staging Classification and the New WHO Classification for Cancer of the Ovary

2017 ◽  
Vol 32 (1) ◽  
pp. 33-41
Author(s):  
Ferdousi Begum ◽  
TA Chowdhury
Keyword(s):  
Ovarian Cancer ◽  
Fallopian Tube ◽  
Who Classification ◽  
Transitional Cell ◽  
High Grade ◽  
Cancer Subtypes ◽  
Figo Staging ◽  
Gynecology And Obstetrics ◽  
Intraepithelial Carcinoma ◽  
Staging Classification

Background: The knowledge of different subtypes of ovarian cancer is improving with the progress in molecular pathological research. The WHO classification was revised,in parallel with the implementation of the new FIGO staging classification. The former is mainly based on the histopathological findings and defines the actual type of tumor. It has an important impact on prognosis and therapy of the patient. Materials and methods: FIGO staging classification for cancer of the ovary, fallopian tube, and peritoneum published by Jaime Prat and the new WHO Classification of Ovarian Cancer published by Robert Kurman and coauthors in 2014 are summarized. Results: The International Federation of Gynecology and Obstetrics recently significantly revised staging criteria for cancer of the ovary. The latest revision was based on the concept that high-grade serous tubal intraepithelial carcinoma (STIC) may be the origin of some high-grade serous carcinomas of the ovary and peritoneum. Therefore, staging criteria for the ovary, fallopian tube, and peritoneum have been unified. Understanding this background and other important revised points are essential. The previous focus of mesothelial origin of ovarian cancer has been eliminated in new classification. Instead, a discussion of tubal carcinogenesis of hereditary and some other high-grade serous carcinomas is featured. Regarding serous cancers, the previously assumed pathogenesis pathway may be correct for some, but not for all. The earlier transitional cell type of ovarian cancer has been removed while seromucinous tumors have been added as a new entity. The role of some borderline tumors as one possible step in the progression from benign to invasive lesions is incorporated. The article summarizes the essential updates concerning serous, mucinous, seromucinous, endometrioid, clearcell, and Brenner tumors. Conclusion: The new WHO classification takes into account the recent findings on the origin, pathogenesis, and prognosis of different ovarian cancer subtypes. In both FIGO and WHO classification, the tubal origin of hereditary and some non-hereditary high-grade serous cancers is mentioned in contrast to the hitherto theory of mesothelial origin of tumors. Seromucinous tumors represent a new entity. Bangladesh J Obstet Gynaecol, 2017; Vol. 32(1): 33-41

scholarly journals Low-Grade Ovarian Serous Adenocarcinoma with Lymph Node Metastasis in Neck

Diagnostics ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1804
Author(s):  
Shih-Lung Chen ◽  
Tsan-Yu Hsieh ◽  
Shih-Wei Yang
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Neck Mass ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Serous Adenocarcinoma ◽  
Ovarian Serous Adenocarcinoma ◽  
The Right ◽  
Radioactivity Uptake

Low-grade ovarian serous adenocarcinoma is rarely encountered in the neck region. The diagnosis of this rare malignancy entity in the neck is challenging for both clinicians and pathologists. A 53-year-old female with a chief complaint of a right lower neck mass that had been growing for approximately 2 weeks. The ultrasound-guided fine needle aspiration cytology favored malignancy. The positron emission tomography/computed tomography scan revealed the clustered enlarged lymph nodes with increased radioactivity uptake in the right neck level V, and strong radioactivity uptake was also displayed in the right ovarian regions. Pelvis magnetic resonance imaging displayed right adnexal complex mass supporting the ovarian cancer. An en bloc resection of the right neck lymph node was conducted. Ovarian serous adenocarcinoma with metastasis of lymph nodes in the neck was confirmed through histopathological findings. This study reviews the clinical features of low-grade ovarian serous carcinoma metastasizing to lymph nodes in neck. Although very rare, ovarian cancer with neck metastasis should be considered in the differential diagnosis of a neck mass lesion. The clinical staging would be relatively high due to the quiet entity of the cancer.

scholarly journals Sister Mary Joseph Nodule as a First Manifestation of a Metastatic Ovarian Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
Giannina Calongos ◽  
Mai Ogino ◽  
Takatoshi Kinuta ◽  
Masateru Hori ◽  
Tatsuo Mori
Keyword(s):  
Ovarian Cancer ◽  
Differential Diagnosis ◽  
Treatment Initiation ◽  
Imaging Studies ◽  
Serous Adenocarcinoma ◽  
Umbilical Metastasis ◽  
Prompt Treatment ◽  
Ovarian Serous Adenocarcinoma ◽  
Abdominal Lesions ◽  
Sister Mary Joseph

A 76-year-old female presented to our hospital with a 2 cm firm, nontender, protuberant umbilical nodule. She received treatment with antibiotics for suspected granuloma, with no improvement after two months. High levels of CA125 as well as an ovarian cyst and intrathoracic and intra-abdominal lesions on imaging studies made us suspect an ovarian cancer with a Sister Mary Joseph nodule (SMJN) and other metastases. A bilateral salpingo-oophorectomy and umbilical and omentum tumor resections were performed and a metastatic ovarian serous adenocarcinoma was diagnosed by histopathology. After surgery, the patient received chemotherapy with paclitaxel, carboplatin, and bevacizumab; however paclitaxel allergy was observed. As a result, chemotherapy continued with carboplatin and bevacizumab every three weeks for a total of 6 courses. Currently, she is still undergoing treatment with bevacizumab and CA125 levels have been progressively decreasing. SMJN is a rare umbilical metastasis which needs to be considered as a differential diagnosis in the presence of an umbilical tumor for prompt treatment initiation.

A case of ovarian serous adenocarcinoma with tubal intraepithelial carcinoma

2015 ◽  
Vol 54 (5) ◽  
pp. 318-322
Author(s):  
Jun KIKUCHI ◽  
Masanori YASUDA ◽  
Tomomi KATO ◽  
Yasuo KAMAKURA ◽  
Tomoko SAZE ◽  
...  
Keyword(s):  
Serous Adenocarcinoma ◽  
Ovarian Serous Adenocarcinoma ◽  
Intraepithelial Carcinoma

scholarly journals RETRACTED ARTICLE: Correlation of CD44v6 expression with ovarian cancer progression and recurrence

BMC Cancer ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Jun Shi ◽  
Zhou Zhou ◽  
Wen Di ◽  
Ningli Li
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Progression ◽  
Early Stage ◽  
Serous Adenocarcinoma ◽  
Potential Association ◽  
Skov3 Cells ◽  
Ovarian Serous Adenocarcinoma ◽  
And Migration ◽  
Cd44v6 Expression

Abstract Background Previously some groups demonstrated that CD44 variant 6 (CD44v6) is correlated with progression and metastasis of ovarian cancer. However, a number of other groups failed to find such an association. Moreover, epithelial ovarian cancer is known to easily metastasize to distinct sites such as the pelvic and abdominal cavities, but the potential association of CD44v6 expression with site-specific metastasis of ovarian cancer has not been explored. This study sought to evaluate the expression of CD44 standard (CD44s) and CD44v6 in primary, metastatic and recurrent epithelial ovarian cancer to explore the potential association of CD44s and CD44v6 with tumor progression and recurrence. Methods Tumor specimens were procured from patients with advanced (FIGO III, G3) and recurrent ovarian serous adenocarcinoma. CD44s and CD44v6 expression in the tumor tissues was evaluated by real-time RT-PCR and Western blot. Moreover, serum soluble CD44s or CD44v6 concentrations of early stage (FIGO I, G1), advanced (FIGO III, G3) and recurrent ovarian serous adenocarcinoma patients were determined by enzyme-linked immunosorbent assays (ELISA). CD44v6 expression in a different set of tumor samples on an ovarian cancer tissue chip was evaluated by immunohistochemistry (IHC) and the correlation of CD44v6 expression with clinicopathologic features was analyzed. Finally, the effects of knockdown of CD44v6 in SKOV3 cells on cell adhesion, invasion and migration were assessed. Results The expression of CD44v6, but not CD44s, is up-regulated in recurrent ovarian serous cancer compared to advanced primary tumor. CD44v6 expression is also preferentially increased in the tumor at the abdominal cavity metastasis site of advanced diseases. Consistently, serum soluble CD44v6 levels of recurrent ovarian cancer were higher than those of early stage and advanced primary diseases. The IHC data demonstrate that CD44v6 expression is correlated with clinicopathologic features and tumor progression. Lastly, knockdown of CD44v6 decreases the adhesion and migration but not invasion capacities of SKOV3 cells. Conclusions CD44v6 expression levels are associated with epithelial ovarian cancer progression, metastasis and relapse. Moreover, serum soluble CD44v6 may be used as a potential marker for identifying tumor relapse. Finally, CD44v6 may play a role in ovarian cancer metastasis by mediating tumor cell adhesion and migration.

Sign in / Sign up

Export Citation Format

Share Document